Evidence map›Paper›PMID 37242451›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Exploration of Novel Urolithin C Derivatives as Non-Competitive Inhibitors of Liver Pyruvate Kinase.

Umberto Maria Battisti, Leticia Monjas, Fady Akladios, Josipa Matic, Eric Andresen, Carolin H Nagel, Malin Hagkvist, Liliana Håversen, Woonghee Kim, Mathias Uhlen and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Genome-scale models in human metabologenomics.Nature reviews. Genetics · 2025
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Umberto Maria BattistiDepartment of Chemistry and Molecular Biology, University of Gothenburg, SE-412 96 Gothenburg, Sweden.ORCID 0000-0002-1012-8644
Leticia MonjasDepartment of Chemistry and Molecular Biology, University of Gothenburg, SE-412 96 Gothenburg, Sweden.
Fady AkladiosDepartment of Chemistry and Molecular Biology, University of Gothenburg, SE-412 96 Gothenburg, Sweden.
Josipa MaticDepartment of Chemistry and Molecular Biology, University of Gothenburg, SE-412 96 Gothenburg, Sweden.ORCID 0000-0003-1774-0446
Eric AndresenDepartment of Chemistry and Molecular Biology, University of Gothenburg, SE-412 96 Gothenburg, Sweden.
Carolin H NagelDepartment of Chemistry and Molecular Biology, University of Gothenburg, SE-412 96 Gothenburg, Sweden.
Malin HagkvistDepartment of Chemistry and Molecular Biology, University of Gothenburg, SE-412 96 Gothenburg, Sweden.
Liliana HåversenDepartment of Molecular and Clinical Medicine, University of Gothenburg, SE-413 45 Gothenburg, Sweden.ORCID 0000-0001-5180-7830
Woonghee KimScience for Life Laboratory, KTH-Royal Institute of Technology, SE-171 65 Stockholm, Sweden.
Mathias UhlenScience for Life Laboratory, KTH-Royal Institute of Technology, SE-171 65 Stockholm, Sweden.
Jan BorénDepartment of Molecular and Clinical Medicine, University of Gothenburg, SE-413 45 Gothenburg, Sweden.ORCID 0000-0003-0786-8091
Adil MardinoğluScience for Life Laboratory, KTH-Royal Institute of Technology, SE-171 65 Stockholm, Sweden.ORCID 0000-0002-4254-6090
Morten GrøtliDepartment of Chemistry and Molecular Biology, University of Gothenburg, SE-412 96 Gothenburg, Sweden.ORCID 0000-0003-3621-4222
Science for Life Laboratory · SEUniversity of Gothenburg · SESahlgrenska University Hospital · SEKing's College London · GB

Funding

Knut and Alice Wallenberg Foundation proof-of-concept grantOgonoris Foundation 0063869ScandiEdge Therapeutics AB there is noSwedish Research Council 2019-01049Torsten Söderberg Foundation M105/19
6 · The paper itself

Abstract

The inhibition of liver pyruvate kinase could be beneficial to halt or reverse non-alcoholic fatty liver disease (NAFLD), a progressive accumulation of fat in the liver that can lead eventually to cirrhosis. Recently, urolithin C has been reported as a new scaffold for the development of allosteric inhibitors of liver pyruvate kinase (PKL). In this work, a comprehensive structure-activity analysis of urolithin C was carried out. More than 50 analogues were synthesized and tested regarding the chemical features responsible for the desired activity. These data could pave the way to the development of more potent and selective PKL allosteric inhibitors.

Indexed as

allosteric inhibitorsliver pyruvate kinaseNAFLDSAR studiesurolithin C

Identifiers

PMID37242451
PMCPMC10224133
OpenAlexW4367319487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.